Mindy Valcarcel

Aditya Bardia, MD, has been appointed to multiple leadership roles at David Geffen School of Medicine at UCLA and UCLA Health Jonsson Comprehensive Cancer Center.Bardia will serve as director of the breast cancer clinical and research programs.

Susan Tsai, MD, has been appointed chief of the division of surgical oncology at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Tsai, whose appointment takes effect Nov. 1, also will serve as professor of surgery in the college of medicine.

Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to topline data released by the agent’s manufacturer. Milademetan (Rain Oncology) is an oral, small-molecule murine double minute-2 (MDM2) inhibitor that reactivates p53.

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.Perales — chief of the adult bone marrow transplantation service at Memorial Sloan Kettering Cancer Center and professor of medicine at Weill Cornell Medical College — will direct the society’s new strategic plan and provide more science focus to

Friends of Cancer Research appointed Edward S. Kim, MD, MBA, FACP, FASCO, to its board of directors.Kim — an associate medical editor for Healio | HemOnc Today — is physician-in-chief and senior vice president of City of Hope Orange County. He also is vice physician-in-chief and professor with City of Hope National Medical Center.

The FDA announced several regulatory actions the past few weeks. Here is an overview of decisions that may be relevant to your practice.

Healio | HemOnc Today is excited to announce a new physician leadership structure, which features seven Associate Medical Editors from various subspecialty areas within oncology and hematology.The new senior leadership board — which will guide Healio | HemOnc Today ’s Editorial Board — will assist in content selection and act as ambassadors for the publication.

A phase 3 trial of trilaciclib in combination FOLFOXIRI and bevacizumab for patients with metastatic colorectal cancer met its co-primary endpoints but will be terminated based on early efficacy data, according to the agent’s manufacturer.The pivotal randomized, placebo-controlled PRESERVE 1 trial of trilaciclib (Cosela, G1 Therapeutics) achieved its primary endpoints related to severe

The FDA announced several regulatory actions the past few weeks.Here is an overview of decisions that may be relevant to your practice.

World Cancer Day is observed annually on Feb. 4.The theme of this year’s observance once again is “Close the Care Gap.”